首页    期刊浏览 2024年12月14日 星期六
登录注册

文章基本信息

  • 标题:Efficacy Of Pegylated Interferon And Ribavirin Treatment In Coinfected HIV HCV Patients
  • 本地全文:下载
  • 作者:Irina Magdalena Dumitru ; Eugen Dumitru ; Liliana Ana Tuta
  • 期刊名称:ARS Medica Tomitana
  • 电子版ISSN:1841-4036
  • 出版年度:2017
  • 卷号:23
  • 期号:1
  • 页码:47-52
  • DOI:10.1515/arsm-2017-0009
  • 语种:English
  • 出版社:Walter de Gruyter GmbH
  • 摘要:The objectives of the study were to determine the efficacy of pegylated interferon alfa 2 b (PegINF) and ribavirin (RBV) treatment in co-infected HIV / HCV patients, to identify predictive factors associated with sustained viral response (SVR) in these patients. Out of the 956 HIV infected patients, 38 were HCVAb (4%) positive, 14 of which had undetectable HCV RNA, only 6 patients met the inclusion criteria. Screening failure was due to: liver cirrhosis Child Pugh B / C, hepatocellular carcinoma, pulmonary TB, thyroid dysfunction, CD4 <200 cells3, detectable HIV RNA and depressive syndrome. We initiated PegINF and RBV therapy for 48 weeks. SVR was achieved in 16.6% of cases (only one patient) and correlated with HCV RNA level, CD4 count, duration of HIV infection, CDC classification and liver fibrosis. In conclusion, our study group has a low prevalence of HIV / HCV co-infection (2.6%) with a large number of patients HCVAb positive but undetectable HCV RNA. Positive predictive factors for SVR were: low levels of HCV RNA, small duration of HIV infection, high levels of CD4, B1/B2 (CDC classification) and low degree of fibrosis.
  • 关键词:HIV/ HCV coinfection ; antiviral treatment ; SVR
国家哲学社会科学文献中心版权所有